Daybue is the first FDA-approved oral treatment for Rett syndrome in patients 2 years of age and older. It targets neurological function to address core symptoms of the disorder.
To Get Full Access :
To Get Full Access :
Daybue is the first FDA-approved oral treatment for Rett syndrome in patients 2 years of age and older. It targets neurological function to address core symptoms of the disorder.
The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
